{"id":892393,"title":"Archived - CCDR: Volume 44-7/8, July 5, 2018: Can we eliminate hepatitis C? - Canada.ca","sourceCode":"phac","sourceName":"Public Health Agency of Canada","language":"en","captureDate":"2026-03-05","captureTimestamp":"2026-03-05T23:59:42.550000+00:00","jobId":7,"originalUrl":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2018-44/issue-7-8-july-5-2018.html","snippet":"Archived - CCDR: Volume 44-7/8, July 5, 2018: Can we eliminate hepatitis C? Table of contents Database Study Impact of availability of direct-acting antivirals for hepatitis C on Canadian hospitalization rates, 2012–2016 D Schanzer, L Pogany, J Aho, K Tomas, M Gale-Rowe, JC…","rawSnapshotUrl":"/api/snapshots/raw/892393","browseUrl":"https://replay.healtharchive.ca/job-7/20260305235942/https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2018-44/issue-7-8-july-5-2018.html#ha_snapshot=892393","mimeType":"text/html","statusCode":200,"captureBackend":"playwright_warc","captureFidelity":"fallback"}